<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ro">
	<id>https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=Dicerna_Pharmaceuticals%2C_Inc.</id>
	<title>Dicerna Pharmaceuticals, Inc. - Revizia istoricului</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=Dicerna_Pharmaceuticals%2C_Inc."/>
	<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=Dicerna_Pharmaceuticals,_Inc.&amp;action=history"/>
	<updated>2026-05-19T08:39:26Z</updated>
	<subtitle>Istoricul versiunilor pentru această pagină din wiki</subtitle>
	<generator>MediaWiki 1.39.2</generator>
	<entry>
		<id>https://wiki.tradeville.ro/index.php?title=Dicerna_Pharmaceuticals,_Inc.&amp;diff=416767&amp;oldid=prev</id>
		<title>Admin: Pagină nouă: Pagina dedicata companiei Dicerna Pharmaceuticals, Inc. listata cu simbolul US.DRNA  ==Descriere companie== Dicerna Pharmaceuticals Inc (www.dicerna.com) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platform GalXCTM is an advanced next-generation RNAi-based therapies that i...</title>
		<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=Dicerna_Pharmaceuticals,_Inc.&amp;diff=416767&amp;oldid=prev"/>
		<updated>2024-09-18T17:51:19Z</updated>

		<summary type="html">&lt;p&gt;Pagină nouă: Pagina dedicata companiei Dicerna Pharmaceuticals, Inc. listata cu simbolul US.DRNA  ==Descriere companie== Dicerna Pharmaceuticals Inc (www.dicerna.com) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platform GalXCTM is an advanced next-generation RNAi-based therapies that i...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Pagină nouă&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Pagina dedicata companiei Dicerna Pharmaceuticals, Inc. listata cu simbolul US.DRNA&lt;br /&gt;
&lt;br /&gt;
==Descriere companie==&lt;br /&gt;
Dicerna Pharmaceuticals Inc (www.dicerna.com) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platform GalXCTM is an advanced next-generation RNAi-based therapies that is designed to silence disease-driving genes in the liver. Dicerna’s GalXC-based therapies are processed by the Dicer enzyme, which is the natural initiation point for RNAi within the human cell. The company also develops therapies to treat diseases linking the liver includes rare, viral infections, chronic liver, and cardiovascular diseases. Dicerna is headquartered in Lexington, Massachusetts, the US.&lt;br /&gt;
&lt;br /&gt;
==Grafic actiuni companie==&lt;br /&gt;
&amp;lt;iframe key=&amp;quot;tradeville&amp;quot; path=&amp;quot;graficSimbol/US.DRNA&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Ultimele stiri despre Dicerna Pharmaceuticals, Inc. (US.DRNA)==&lt;br /&gt;
&amp;lt;dynamicpagelist&amp;gt;&lt;br /&gt;
category=US.DRNA&lt;br /&gt;
count=10&lt;br /&gt;
order=descending&lt;br /&gt;
addfirstcategorydate=false&lt;br /&gt;
&amp;lt;/dynamicpagelist&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Categorie:US.DRNA]][[Categorie:Stiri despre companii]]&lt;/div&gt;</summary>
		<author><name>Admin</name></author>
	</entry>
</feed>